Magle Group today issues a profit warning in advance of the publication of its Q4 2025 Interim Report and Full-Year 2025 Results, now scheduled for release on March 27, 2026.
This follows the Group's strategic refocus announced on January 29, 2026, in which Magle Group outlined a renewed commitment to profitability, operational discipline, and long-term value creation. As part of this transformation, the Company is conducting a comprehensive operational review, which includes the impairment of non-core assets, streamlining of operations, and realignment of its portfolio.
Preliminary Financial Expectations for Q4 and FY 2025
The Company expects to report:
- Full-year 2025 Revenue of approximately 300 MSEK (compared to 256 MSEK in 2024)
- Q4 2025 Revenue of approximately 85 MSEK (compared to 84 MSEK in 2024)
- Full-year 2025 EBITDA of approximately negative 10 MSEK (compared to 59 MSEK in 2024)
- Q4 2025 EBITDA of approximately negative 42 MSEK (compared to 20 MSEK in 2024), reflecting restructuring costs, impairments, and asset write-downs
These figures are unaudited and subject to finalisation ahead of the formal reporting date.
Aaron Wong, Interim Chief Executive Officer, commented:
"The short-term financial impact we are announcing today is the direct consequence of decisive action. We are simplifying the business, shedding complexity, and focusing on our most scalable and profitable segments - Magle Biopolymers and Magle Chemoswed. These measures, while painful in the near term, will enable stronger, more sustainable performance moving forward."
Key Drivers of the Profit Warning
- Impairment of early-stage biotech assets and pipeline projects that are no longer aligned with Magle Group's core strategy;
- Restructuring and redundancy costs associated with operational consolidation and organisational realignment;
- Inventory write-downs and exit costs from discontinued or deprioritised business lines.
These are primarily non-recurring, non-cash charges and reflect a strategic commitment to sharpening commercial focus and improving capital efficiency.
Forward Strategy
The Group will now prioritise revenue generation from its Biopolymer and CDMO businesses, with a disciplined approach to R&D and capital allocation. Future innovation will be tightly linked to commercial readiness and scalability.
A stakeholder Q&A and strategy session with Interim CEO Aaron Wong will be scheduled following the Q4 2025 report to ensure transparency and alignment with the Group's forward-looking priorities.
Contacts Aaron
Aaron Wong, Interim CEO, CFO, phone +46 (0)76 664 35 79, aaron.wong@maglegroup.com
About Us
The Magle Group aims to establish itself as a leader in high-quality life-changing healthcare innovations to meet medical needs through scientific excellence. The Magle Group is founded on strategic acquisitions aimed at driving growth and diversifying risk. Today, the Group includes three operational areas. Magle Chemoswed - a contract development and manufacturing organization (CDMO) with a strong reputation for its high-quality development and manufacturing expertise and Magle PharmaCept - an established sales and marketing company for development and direct sales of the Groups medical technology products. Magle Biopolymers A/S- a specialized manufacturing organization of Dextran technology. Learn more on www.maglechemoswed.com and www.maglegroup.com and www.maglepharmacept.com and www.maglebiopolymers.com
Redeye Sweden AB is the company's Certified Adviser.
This information is information that Magle Chemoswed is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact persons set out above, at 2026-02-18 18:00 CET.
